Altimmune (ALT) Net Cash Flow (2010 - 2026)
Altimmune (ALT) reported Net Cash Flow of $53.8 million for Q1 2026, up 342.12% year-over-year from $12.2 million in Q1 2025, and up 408.09% on a QoQ basis from -$17.5 million in Q4 2025.
Altimmune (ALT) has 17 years of Net Cash Flow data on file, last reported at $53.8 million in Q1 2026.
- Quarterly Net Cash Flow rose 342.12% year-over-year to $53.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.5 million (up 262.34% YoY) and the FY2025 annual result came in at $6.8 million, up 106.96% from the prior year.
- Net Cash Flow rose to $53.8 million in Q1 2026 per ALT's latest filing, from -$17.5 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $134.0 million in Q2 2025 and bottomed at -$121.9 million in Q3 2025.
- The 5-year median for Net Cash Flow is -$10.4 million (2022), against an average of -$5.5 million.
- The widest annual swing landed in 2022, when Net Cash Flow tumbled 1202.89%; it then soared 713.28% in 2025.
- Tracing ALT's Net Cash Flow over 5 years: stood at -$16.4 million in 2022, then surged by 394.86% to $48.3 million in 2023, then slumped by 88.7% to $5.5 million in 2024, then plunged by 420.54% to -$17.5 million in 2025, then jumped by 408.09% to $53.8 million in 2026.
- Per Business Quant, the three latest ALT Net Cash Flow figures stand at $53.8 million (Q1 2026), -$17.5 million (Q4 2025), and -$121.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 625.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 457.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -152.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 60.68 Mn |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - | 53.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53.84 Mn |
| Mar 31, 2026 | 53.84 Mn |
| Dec 31, 2025 | -17.48 Mn |
| Dec 31, 2025 | -17.48 Mn |
| Sep 30, 2025 | -121.87 Mn |
| Sep 30, 2025 | -121.87 Mn |
| Jun 30, 2025 | 134.00 Mn |
| Jun 30, 2025 | 134.00 Mn |
| Mar 31, 2025 | 12.18 Mn |
| Mar 31, 2025 | 12.18 Mn |
| Dec 31, 2024 | 5.45 Mn |
| Dec 31, 2024 | 5.45 Mn |
| Sep 30, 2024 | -25.65 Mn |
| Sep 30, 2024 | -25.65 Mn |
| Jun 30, 2024 | -21.85 Mn |
| Jun 30, 2024 | -21.85 Mn |
| Mar 31, 2024 | -56.14 Mn |
| Mar 31, 2024 | -56.14 Mn |
| Dec 31, 2023 | 48.26 Mn |
| Dec 31, 2023 | 48.26 Mn |
| Sep 30, 2023 | -15.50 Mn |
| Sep 30, 2023 | -15.50 Mn |
| Jun 30, 2023 | -2.33 Mn |
| Jun 30, 2023 | -2.33 Mn |
| Mar 31, 2023 | -6.41 Mn |
| Mar 31, 2023 | -6.41 Mn |
| Dec 31, 2022 | -16.37 Mn |
| Dec 31, 2022 | -16.37 Mn |
| Sep 30, 2022 | -8.39 Mn |
| Sep 30, 2022 | -8.39 Mn |
| Jun 30, 2022 | -44.09 Mn |
| Jun 30, 2022 | -44.09 Mn |
| Mar 31, 2022 | -10.35 Mn |
| Mar 31, 2022 | -10.35 Mn |
| Dec 31, 2021 | 15.44 Mn |
| Dec 31, 2021 | 15.44 Mn |
| Sep 30, 2021 | 761,000.00 |
| Sep 30, 2021 | 761,000.00 |
| Jun 30, 2021 | 24.17 Mn |
| Jun 30, 2021 | 24.17 Mn |
| Mar 31, 2021 | 34.02 Mn |
| Mar 31, 2021 | 34.02 Mn |
| Dec 31, 2020 | -27.58 Mn |
| Dec 31, 2020 | -27.58 Mn |
| Sep 30, 2020 | 78.75 Mn |
| Sep 30, 2020 | 78.75 Mn |
| Jun 30, 2020 | 53.47 Mn |
| Jun 30, 2020 | 53.47 Mn |
| Mar 31, 2020 | 2.31 Mn |
| Mar 31, 2020 | 2.31 Mn |
| Dec 31, 2019 | -2.01 Mn |
| Dec 31, 2019 | -2.01 Mn |
| Sep 30, 2019 | -30.70 Mn |
| Sep 30, 2019 | -30.70 Mn |
| Jun 30, 2019 | -3.23 Mn |
| Jun 30, 2019 | -3.23 Mn |
| Mar 31, 2019 | 10.58 Mn |
| Mar 31, 2019 | 10.58 Mn |
| Dec 31, 2018 | 26.35 Mn |
| Dec 31, 2018 | 26.35 Mn |
| Sep 30, 2018 | 3.24 Mn |
| Sep 30, 2018 | 3.24 Mn |
| Jun 30, 2018 | -3.28 Mn |
| Jun 30, 2018 | -3.28 Mn |
| Mar 31, 2018 | -4.21 Mn |
| Mar 31, 2018 | -4.21 Mn |
| Dec 31, 2017 | -4.83 Mn |
| Dec 31, 2017 | -4.83 Mn |
| Sep 30, 2017 | 8.71 Mn |
| Sep 30, 2017 | 8.71 Mn |
| Jun 30, 2017 | 5.62 Mn |
| Jun 30, 2017 | 5.62 Mn |
| Mar 31, 2017 | -145,804.00 |
| Mar 31, 2017 | -145,804.00 |
| Dec 31, 2016 | -2.23 Mn |
| Dec 31, 2016 | -2.23 Mn |
| Sep 30, 2016 | 46,931.00 |
| Sep 30, 2016 | 46,931.00 |
| Jun 30, 2016 | 1.92 Mn |
| Jun 30, 2016 | 1.92 Mn |
| Mar 31, 2016 | -1.33 Mn |
| Mar 31, 2016 | -1.33 Mn |
| Dec 31, 2015 | -1.82 Mn |
| Dec 31, 2015 | -1.82 Mn |
| Sep 30, 2015 | -1.02 Mn |
| Sep 30, 2015 | -1.02 Mn |
| Jun 30, 2015 | 2.67 Mn |
| Jun 30, 2015 | 2.67 Mn |
| Mar 31, 2015 | -2.91 Mn |
| Mar 31, 2015 | -2.91 Mn |
| Dec 31, 2014 | -971,785.00 |
| Dec 31, 2014 | -971,785.00 |
| Sep 30, 2014 | 8.36 Mn |
| Sep 30, 2014 | 8.36 Mn |
| Jun 30, 2014 | 1.73 Mn |
| Jun 30, 2014 | 1.73 Mn |
| Mar 31, 2014 | -945,669.00 |
| Mar 31, 2014 | -945,669.00 |
| Dec 31, 2013 | -5.46 Mn |
| Dec 31, 2013 | -5.46 Mn |
| Sep 30, 2013 | 153,123.00 |
| Sep 30, 2013 | 153,123.00 |
| Jun 30, 2013 | 2.92 Mn |
| Jun 30, 2013 | 2.92 Mn |
| Mar 31, 2013 | 174,572.00 |
| Mar 31, 2013 | 174,572.00 |
| Dec 31, 2012 | -2.02 Mn |
| Dec 31, 2012 | -2.02 Mn |
| Sep 30, 2012 | 2.94 Mn |
| Sep 30, 2012 | 2.94 Mn |
| Jun 30, 2012 | -3.52 Mn |
| Jun 30, 2012 | -3.52 Mn |
| Mar 31, 2012 | 4.06 Mn |
| Mar 31, 2012 | 4.06 Mn |
| Dec 31, 2011 | 984,879.00 |
| Dec 31, 2011 | 984,879.00 |
| Sep 30, 2011 | -3.71 Mn |
| Sep 30, 2011 | -3.71 Mn |
| Jun 30, 2011 | 4.49 Mn |
| Jun 30, 2011 | 4.49 Mn |
| Mar 31, 2011 | -2.07 Mn |
| Mar 31, 2011 | -2.07 Mn |
| Dec 31, 2010 | 9.11 Mn |
| Dec 31, 2010 | 9.11 Mn |
| Sep 30, 2010 | 1.92 Mn |
| Sep 30, 2010 | 1.92 Mn |